SCHEMBL10104451

SCHEMBL10104451

CCN(C)Cc1cc(C)cc(C(F)(F)F)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
PYCR1 P32322 1/20 0.34
HSPA5 P11021 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 1/20 0.33
HTR2A P28223 1/20 0.32
SLC6A4 P31645 1/20 0.32
KCNH2 Q12809 1/20 0.32
S1PR1 P21453 1/20 0.31
RAPGEF4 Q8WZA2 1/20 0.31
CRHR1 P34998 1/20 0.30
SIGMAR1 Q99720 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104437 0.85 SLC6A4 (0.42) NOS3NOS1NOS2PYCR1HSPA5
SCHEMBL10663593 0.79 HSPA5 (0.46) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL10104527 0.75 HSPA5 (0.42) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL10767971 0.75 HSPA5 (0.38) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL15517270 0.73 RAPGEF4 (0.42) HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A
SCHEMBL10104463 0.69 NR1H2 (0.53) SMN1; SMN2
SCHEMBL12124971 0.68 SLC6A2 (0.54) SLC6A4
SCHEMBL10104503 0.68 CYP3A4 (0.39) NOS3NOS1NOS2HSPA5CYP2C9
SCHEMBL10104436 0.68 RORC (0.46) NOS3NOS1NOS2
SCHEMBL10493689 0.68 RAPGEF4 (0.42) PTGS1PTGS2HSPA5SMN1; SMN2RAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 NOS3 545/4885NOS1 676/4885NOS2 1534/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 NOS3 3139/4885NOS1 2364/4885NOS2 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.